Why Mirum Pharmaceuticals, Inc. (MIRM) Stock Fell 7.1% on Sep 18, 2026
What happened
Mirum Pharmaceuticals shares fell 5.85% to $93.04 as investors weigh regulatory uncertainties ahead of a September 26 FDA decision on zilurgisertib for FOP and recent FDA requests for additional Phase 3 clarity on volixibat, according to the web_catalyst synthesis. Volume traded 190,074 shares (0.59x expected for this time of session), reflecting below-average activity despite the decline.
FDA decision on zilurgisertib in FOP scheduled for September 26, 2026; also monitor for updates on volixibat Phase 3 timeline and Q3 2026 earnings (scheduled November 3, consensus EPS −$0.53).
Frequently asked questions
Why did Mirum Pharmaceuticals, Inc. (MIRM) stock fall on Sep 18, 2026?
Mirum Pharmaceuticals shares fell 5.85% to $93.04 as investors weigh regulatory uncertainties ahead of a September 26 FDA decision on zilurgisertib for FOP and recent FDA requests for additional Phase 3 clarity on volixibat, according to the web_catalyst synthesis. Volume traded 190,074 shares (0.59x expected for this time of session), reflecting below-average activity despite the decline.
How much did MIRM stock fall on Sep 18, 2026?
MIRM fell 7.1% during the Sep 18, 2026 trading session.